Survival following HIV infection of a cohort followed up from seroconversion in the UK

AIDS

Volumn 22, Issue 1, 2008, Pages 89-95

  Ewings, Fiona M ^a   Bhaskaran, Krishnan ^a   McLean, Ken ^b   Hawkins, David ^c   Fisher, Martin ^d   Fidler, Sarah ^e   Gilson, Richard ^f   Nock, Demelza ^a   Brettle, Ray ^g   Johnson, Margaret ^h   Phillips, Andrew ^h   Porter, Kholoud ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b London Sexual Health Programme   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UK   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

^f Camden Primary Care Trust   (United Kingdom)

^g NHS LOTHIAN   (United Kingdom)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cohort study; Highly active antiretroviral therapy; HIV seroconversion; Survival

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEROCONVERSION; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM;

EID: 37349124599     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f3915e     Document Type: Article

References (15)

1. CASCADE collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
2. The UK Collaborative Group for HIV and STI Surveillance. A complex picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. London: Health Protection Agency, Centre for Infections; 2006.
3. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20:2371-2379.
4. Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, Puradiredja D, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20:67-71.
5. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al., Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
6. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166:521-528.
7. UK Register of HIV Seroconverters Steering Committee. The UK register of HIV seroconverters: methods and analytical issues. Epidemiol Infect 1996; 117:305-312.
8. Clayton C, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press; 1993.
9. Tyrer F, Walker AS, Gillett J, Porter K, UK Register of Seroconverters. The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohort. Epidemiol Infect 2003; 131:1117-1123.
10. Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis 2007; 39:51-57.
11. Lohse H, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
12. Perez-Hoyos S, Ferreros I, del Amo J, Muga R, del Romero J, de Olalla PG, et al. Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: the effectiveness goes on. AIDS 2006; 20:289-291.
13. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685-692.
14. British HIV Association. BHIVA treatment guidelines. HIV Med 2000; 1:76-101.
15. British HIV Association. BHIVA treatment guidelines. HIV Med 2006; 7:487-503.